An increasing number of studies have shown that pretreatment CEA levels are considered to be associated with tumor stage and metastasis, with studies showing that CEA is elevated in 45% of patients with stage B and 76% of patients with distal metastasis (31–34). This evidence concerns the gene CEACAM5 and neoplasm.